- I am working on updating the INFI research page, so posting to archive these Infinity Pharma webcast notes that did not make it onto the blog earlier.
- IPI926- first ever trial in chondrosarcoma. chemo/radiation not effective. 100 pts 2:1 vs palcebo, PFS endpt
- gemzar is SOC for pancreatic cancer, median survival <6 months. response rate 5-8%
- dense fibrotic shell around tumor...combo with IPI926 allowed gemzar to better perfuse tumor in transgenic mouse model- doubled survival
- IPI926 just completed p1b portion- 3 doses of 926 w/ std dose of gemzar (data to be presented asco 2011). 60 pts per arm p2 poriton 1:1
- will announce addl p2 trials this year for IPI-926 (this was the major focus of the presentation, one slide each on other pipeline assets)
- hsp90- IPI504-2 ongoing trials both in NSCLC. One is to try to replicate finding that ALK translocation pts did best in single agent. 2nd is combo with docetaxel (data presented at asco 2011 along with plans for future of this pgm)
- Calistoga- delta specific PI3k inhibitor showed "stunning data." IPI-145 is 10-20x more potent for delta. and adds gamma inhibition too. lots of crosstalk between these isoforms. gamma isoform plays role in trafficing to site of inflammation
- FAAH breaks down anandamide- mol produced to relieve pain.IPI- 940- blocks this enzyme, get more natural analgesia. same MOA as medical marijuana
- tx this pgm differently compared to other assets, transfer to purdue now as starting p2
- hsp90 pgm was partnered when the mundi/purdue partneship put into place- therefore is excluded and self-funded
- sufficient cash and committed funding to drive pgms thru value inflection and into 2014
RSS Feed
